Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA-seq of aortas from mice with Wnk1 deletion in vascular smooth muscle cells (experiment 2)

ABSTRACT: scRNA-seq of aortas from mice with Wnk1 deletion in vascular smooth muscle cells (experiment 2)

PROVIDER: PRJNA1114720 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

scRNA-seq of aortas from mice with Wnk1 deletion in vascular smooth muscle cells (experiment 2)

Project description:scRNA-seq of total cells from aortas of mice with Wnk1 deletion in vascular smooth muscle cells

2024-06-24 | GSE268125 | GEO

scRNA-seq of aortas from mice with Wnk1 deletion in vascular smooth muscle cells (experiment 1)

Project description:scRNA-seq of total cells from aortas of mice with Wnk1 deletion in vascular smooth muscle cells

2024-06-24 | GSE265761 | GEO

scRNA-seq of aortas from mice with Wnk1 deletion in vascular smooth muscle cells (experiment 1)

Project description:scRNA-seq of aortas from mice with Wnk1 deletion in vascular smooth muscle cells (experiment 1)

| PRJNA1104151 | ENA

Effect of IL-17 on human vascular smooth muscle cells

Project description:Investigate the effect of recombinant human IL-17A on vascular smooth muscle cells cultured from human aortas. Keywords: Dose response

2008-06-28 | GSE11367 | GEO

Vascular smooth muscle selective deletion of Srf

Project description:Vascular smooth muscle selective deletion of Srf

| PRJNA577451 | ENA

Transcription profiling by array of human aortic vascular smooth muscle cells treated with IL-17 or untreated

Project description:Investigate the effect of recombinant human IL-17A on vascular smooth muscle cells cultured from human aortas. Experiment Overall Design: SMCs from the aortas of three different donors were cultured in M199 media supplemented with 20% FCS and used at passage 3. The cells were either not treated or treated with IL-17 at 100 ng/ml for 6 hr. The six samples were labeled as Untreated or IL-17-treated from three independent experiments labeled A, B, and C.

2008-10-24 | E-GEOD-11367 | biostudies-arrayexpress

Transcriptome analaysis of Bcl11b-deficient aortas

Project description:B-cell leukemia 11b (BCL11B) is a transcription factor known as an essential regulator of T lymphocytes and neuronal development during embryogenesis. A genome-wide association study (GWAS) showed that a gene desert region downstream of BCL11B, known to function as a BCL11B enhancer, harbors single nucleotide polymorphisms (SNPs) associated with increased arterial stiffness. However, a role for BCL11B in the adult cardiovascular system is unknown. Based on these human findings, we sought to examine the relation between BCL11B and arterial function. Here we report that BCL11B is expressed in the vascular smooth muscle (VSM) where it regulates vascular stiffness. RNA sequencing of aortas from WT and Bcl11b null mice (BSMKO) identified the cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) as the most significant differentially regulated signaling pathway in BSMKO compared to WT mice. BSMKO aortas showed decreased levels of PKG1, increased levels of Ca++-calmodulin-dependent serine/threonine phosphatase calcineurin (PP2B) and their common phosphorylation target, vasodilator-stimulated phosphoprotein (pVASPS239), a regulator of cytoskeletal actin rearrangements. Decreased pVASPS239 in BSMKO aortas was associated with increased actin polymerization (F/G actin ratio). Functionally, aortic force, stress, wall tension and stiffness, measured ex vivo in organ baths, were increased in BSMKO aortas, and BSMKO mice had increased pulse wave velocity, the in vivo index of arterial stiffness. Despite having no effect on blood pressure or microalbuminuria, increased arterial stiffness in BSMKO mice was associated with increased incidence of cerebral microbleeds compared to age-matched WT littermates. In conclusion, we have identified VSM BCL11B as a crucial regulator of aortic smooth muscle function and a potential therapeutic target for vascular stiffness.

2021-12-01 | GSE163551 | GEO

Whole transcriptome analysis of mouse aortas and kidneys with or without deletion of the EGFR in vascular smooth muscle cells after 18 weeks of high fat diet

Project description:Obesity causes diabetes type 2 (DMT2) leading to vascular dysfunction and finally renal end-organ damage. Vascular smooth muscle (VSM) EGF receptor (EGFR) modulates vascular wall homeostasis in part via serum response factor (SRF), a major regulator of VSM differentiation and a sensor for glucose. We investigated the role of VSM-EGFR during obesity-induced renovascular dysfunction and the EGFR-hyperglycemia crosstalk.

2020-03-01 | GSE144838 | GEO

LncVSM (AK098656) down-regulation in Vascular Smooth Muscle cells

Project description:The full length of LncVSM transfected into Vascular Smooth Muscle cells to down-regulation for screening differential expression prolifes of LncVSM effecting.The empty vector transfected Vascular Smooth Muscle cells as controls. Eight Samples analyzed.

2016-01-12 | E-GEOD-76720 | biostudies-arrayexpress

YAP/TAZ in vascular smooth muscle

Project description:YAP/TAZ in vascular smooth muscle

| PRJNA610067 | ENA